Vizsgálati helyszín
Florida Research Institute
Lakewood Rch, Florida 34211, Egyesült ÁllamokMég nincs intézményhez kötve
- 16futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis12 vizsgálat
- 3. fázis10 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Lezárult8 vizsgálat
- Toboroz7 vizsgálat
- Leállították2 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Eli Lilly and Company4 vizsgálat
- Madrigal Pharmaceuticals, Inc.4 vizsgálat
- Boehringer Ingelheim3 vizsgálat
- Gilead Sciences3 vizsgálat
- Inventiva Pharma2 vizsgálat
- és még 10
Futó vizsgálatok
Még nem toboroz
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
NCT07848191· 4. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Contact: Tom Hare
Toboroz
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
NCT07841977· 2. fázis· Gilead Sciences· Forrás
Toboroz
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· 2. fázis· Eli Lilly and Company· Forrás
Contact: Manuel Rodriguez (principal investigator)
Toboroz
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· 2. fázis· Eli Lilly and Company· Forrás
Contact: Manuel Rodriguez (principal investigator)
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Manuel Rodriguez (principal investigator)
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656· 2. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· 2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222· 3. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· 3. fázis· Inventiva Pharma· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219· 3. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308· 2. fázis· Mirum Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
NCT04136002· Guardant Health, Inc.· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429· 3. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
NCT06247735· 2. fázis· Kowa Research Institute, Inc.· Forrás
Lezárult
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
NCT06060665· 3. fázis· Gilead Sciences· Forrás
Lezárult
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
NCT05232071· 2. fázis· Inventiva Pharma· Forrás
Lezárult
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
NCT05104853· 1/2. fázis· COUR Pharmaceutical Development Company, Inc.· Forrás
Lezárult
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· 2. fázis· Gilead Sciences· Forrás
Leállították
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
NCT04267393· 2. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
NCT04480840· 2. fázis· Pliant Therapeutics, Inc.· Forrás
Leállították
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
NCT04365868· 2/3. fázis· Galectin Therapeutics Inc.· Forrás
Lezárult
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
NCT04321031· 2. fázis· Pfizer· Forrás
Lezárult
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
NCT02914535· 3. fázis· Alfasigma S.p.A.· Forrás
Hibát jelzek